ISC 2026 | Key trial updates that will be presented at ISC 2026
In this video, Aristeidis Katsanos, MD, PhD, McMaster University, Hamilton, Canada, shares what he is looking forward to hearing about at the 2026 International Stroke Conference (ISC). This includes key trial updates such as the CHOICE2 (NCT05797792), FASTEST (NCT03496883), and OCEANIC-STROKE (NCT05686070) studies. This interview took place at the 2026 International Stroke Congress (ISC), held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so many interesting trials are going to be presented in this meeting. So we have two interesting trials and I’m looking forward to see the results. So one is, the CHOICE2 trial in ischemic stroke post endovascular thrombectomy. So there were like very interesting findings from previous trials looking at intra-arterial thrombolysis with different thrombolytic agents so I think this trial is going to be very important it’s going to shed further light and the other one is the FASTEST trial looking at the recombinant Factor VII after intracerebral hemorrhage and in the hyperacute period after the ICH and looking forward to see results...
Yeah, so many interesting trials are going to be presented in this meeting. So we have two interesting trials and I’m looking forward to see the results. So one is, the CHOICE2 trial in ischemic stroke post endovascular thrombectomy. So there were like very interesting findings from previous trials looking at intra-arterial thrombolysis with different thrombolytic agents so I think this trial is going to be very important it’s going to shed further light and the other one is the FASTEST trial looking at the recombinant Factor VII after intracerebral hemorrhage and in the hyperacute period after the ICH and looking forward to see results. Tomorrow we also have a very important study that’s going to be presented by one of my colleagues, Dr Mike Sharma, and this is the OCEANIC-STROKE trial, testing Factor XI on top of standard medical care for secondary stroke prevention. So, of course, there are many other trials and many other, you know, research and studies that are going to be presented, so I’m looking forward to the results of those studies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
